| Budget Amount *help |
¥17,550,000 (Direct Cost: ¥13,500,000、Indirect Cost: ¥4,050,000)
Fiscal Year 2020: ¥4,290,000 (Direct Cost: ¥3,300,000、Indirect Cost: ¥990,000)
Fiscal Year 2019: ¥4,680,000 (Direct Cost: ¥3,600,000、Indirect Cost: ¥1,080,000)
Fiscal Year 2018: ¥8,580,000 (Direct Cost: ¥6,600,000、Indirect Cost: ¥1,980,000)
|
|---|
| Outline of Final Research Achievements |
Liposomal nucleic acid carrier in response to tumor microenvironment has been developed by the surface modification of a novel blood circulating device TGL. Slightly acidic pH sensitive peptide (SAPSP)-modified liposomes showed pH-sensitivity even when the surface hydrophilicity was increased by modifying TGL on their surface. When plasmid DNA was encapsulated into TGL-modified SAPSP-lipo, the expression of exogenous gene in cancer cells was enhanced in response to slightly acidic pH. In tumor penetration type SAPSP (SAPSP-iRGD)-modified liposomes, the tumor penetration of SAPSP-iRGD-lipo was enhanced by their surface modification of TGL. Furthermore, Akt inhibitor encapsulated into TGL-SAPSP-iRGD-lipo induced cell death at slightly acidic pH. Therefore, TGL is a novel blood circulating device capable of improving the surface properties of nanoparticles without inhibiting the function of tumor microenvironment-responsive drug carrier.
|
